[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Hua F, Feng X, Guan Y, Zhao J, Huang Z: Non-Hodgkin's lymphoma of supraclavicular lymph nodes can mimic metastasis of breast cancer during chemotherapy on FDG PET/CT. Clin Nucl Med; 2009 Sep;34(9):594-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of supraclavicular lymph nodes can mimic metastasis of breast cancer during chemotherapy on FDG PET/CT.
  • A 43-year-old woman who had a history of right mastectomy for breast cancer presented with fever and swelling in the right supraclavicular region during her second course of chemotherapy.
  • An FDG PET/CT was performed to evaluate this patient, which revealed mildly increased FDG activity in the lymph node in the supraclavicular region.
  • However, biopsy results demonstrated that the abnormal activity in the right supraclavicular region is due to T-cell lymphoma.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Clavicle. Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / diagnosis. Neoplasm Metastasis / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Lymph Nodes / pathology. Lymph Nodes / radiography. Lymph Nodes / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692820.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


2. Tran BN, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA: Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol; 2003 Sep;90(3):572-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix.
  • PURPOSE: The objective was to evaluate the frequency and prognostic significance of occult supraclavicular lymph node metastases identified by 2-[(18)F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) in patients with cervical carcinoma.
  • PATIENTS AND METHODS: Between March 1998 and January 2002, 186 patients with a new diagnosis of cervical cancer underwent whole-body FDG-PET before therapy.
  • Fourteen patients had abnormal FDG uptake in left supraclavicular lymph nodes without palpable disease.
  • All 14 patients underwent sonographically guided fine-needle aspiration of the left supraclavicular lymph nodes.
  • One patient refused therapy, 6 were treated with palliative intent, and 7 received definitive irradiation and concurrent chemotherapy.
  • RESULTS: The overall frequency of FDG-positive left supraclavicular lymph nodes was 8% (14/186).
  • Therefore, the positive predictive value of abnormal FDG uptake in left supraclavicular lymph nodes was 100%.
  • Nineteen percent of all patients (35/186) had abnormal FDG uptake in para-aortic lymph nodes.
  • The frequency of positive FDG uptake in the left supraclavicular lymph nodes was 40% (14/35) in those with para-aortic lymph node uptake and 15% in those with stage IIIb disease.
  • All patients developed metastatic disease, most commonly to bone and lung.
  • CONCLUSION: The positive predictive value of abnormal FDG uptake in left supraclavicular lymph nodes was 100%.
  • Prognosis for these patients was dismal despite aggressive therapy.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymph Nodes / pathology. Radiopharmaceuticals. Uterine Neoplasms / radionuclide imaging
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13678726.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


3. Fan Y, Xu B, Liao Y, Yao S, Sun Y: A retrospective study of metachronous and synchronous ipsilateral supraclavicular lymph node metastases in breast cancer patients. Breast; 2010 Oct;19(5):365-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective study of metachronous and synchronous ipsilateral supraclavicular lymph node metastases in breast cancer patients.
  • Clinically, ipsilateral supraclavicular lymph node metastasis (ISLM) in breast cancer can be classified into 2 manifestations: metachronous and synchronous.
  • Metachronous ISLM is isolated supraclavicular lymph node relapse after curative treatment.
  • Although both are featured with ipsilateral supraclavicular lymph node metastases they are two clinical entities needing to be addressed differently.
  • Axillary lymph node metastasis status (P = 0.009) and chemotherapy after occurrence of ISLM (P = 0.016) were independent prognostic predictors for metachronous ISLM whilst primary tumor size (P = 0.016) and radiotherapy after diagnosis of ISLM (P = 0.022) were independent prognostic factors for synchronous ISLM.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal / pathology. Carcinoma, Lobular / pathology. Lymphatic Metastasis. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20399657.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


Advertisement
4. Berthold P, Brönnimann M, Wegmüller E: [Primary retroperitoneal seminoma--a rare germ cell neoplasm]. Praxis (Bern 1994); 2000 Feb 10;89(7):291-6
Genetic Alliance. consumer health - Seminoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary retroperitoneal seminoma--a rare germ cell neoplasm].
  • On clinical examination a painless, enlarged supraclavicular lymph node on the left side and small atrophic testes were detected.
  • By biopsy of the retroperitoneal tumor the diagnosis of a seminoma was made, but neither in the orchidectomy specimen of the right side nor in the testicular biopsy of the left side a primary tumor or a scar could be identified.
  • Thus, the diagnosis of a extragonadal primary retroperitoneal seminoma was made.
  • The patient responded well to the combined chemotherapy consisting of cisplatin, bleomycin and etoposide.
  • [MeSH-major] Retroperitoneal Neoplasms / diagnosis. Seminoma / diagnosis
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Diagnostic Imaging. Humans. Male. Retroperitoneal Space / pathology. Testis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10705802.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] SWITZERLAND
  •  go-up   go-down


5. De Ruysscher D, Bremer RH, Koppe F, Wanders S, van Haren E, Hochstenbag M, Geeraedts W, Pitz C, Simons J, ten Velde G, Dohmen J, Snoep G, Boersma L, Verschueren T, van Baardwijk A, Dehing C, Pijls M, Minken A, Lambin P: Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol; 2006 Sep;80(3):307-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial.
  • PURPOSE: To evaluate the patterns of recurrence when elective node irradiation was omitted in patients with limited disease small cell lung cancer (LD-SCLC).
  • Chest radiotherapy to a dose of 45 Gy in 30 fractions in 3 weeks (1.5 Gy BID with 6 - 8 h interval) was delivered concurrently with carboplatin and etoposide chemotherapy.
  • Chest radiation started after a mean time of 17.7 days +/- 9.7 days (SD) (range: 0-33 days) after the beginning of chemotherapy.
  • Only the primary tumour and the positive nodal areas on the pre-treatment CT scan were irradiated.
  • A total of five chemotherapy cycles were administered, followed by prophylactic cranial irradiation (PCI) in patients without disease progression.
  • Isolated nodal failure was defined as recurrence in the regional nodes outside of the clinical target volume, in the absence of in-field failure.
  • RESULTS: After a median time of 18 months post-radiotherapy, 7 patients (26%, 95% CI 19.5-42.5%) developed a local recurrence.
  • Three patients (crude rate 11%, 95% CI 2.4-29%), developed an isolated nodal failure, all of them in the ipsilateral supraclavicular fossa.
  • Eight patients developed an acute, reversible grade 3 (CTC 3.0) radiation oesophagitis (30%, 95% CI 14-50%).
  • CONCLUSIONS: Because of the small sample size, no definitive conclusions can be drawn.
  • However, the omission of elective nodal irradiation on the basis of CT scans in patients with LD-SCLC resulted in a higher than expected rate of isolated nodal failures in the ipsilateral supraclavicular fossa.
  • In the mean time, elective nodal irradiation should only be omitted in clinical trials.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / radiotherapy. Lymph Nodes / radiation effects. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiation Pneumonitis / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949169.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


6. Badzio A, Kurowski K, Karnicka-Mlodkowska H, Jassem J: A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg; 2004 Jul;26(1):183-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer.
  • Even though the response rates to chemotherapy are very high, prognosis of SCLC patients has remained poor with a median survival of only 12-14 months for limited disease.
  • High incidence of local relapses after chemotherapy in limited-stage SCLC led to reassessment of the role of local treatment in the multimodality management of this tumor.
  • METHODS: We performed retrospective comparative analysis of survival in a series of 134 limited-stage SCLC patients treated between 1984 and 1996 with either complete resection followed by chemotherapy (67 patients), or with conventional non-surgical management (67 patients).
  • In all patients who underwent resection, the diagnosis of SCLC was established only postoperatively.
  • The control (non-surgical) group was selected using 'pair-matched case-control' methodology, out of 176 limited-stage patients potentially suitable for surgery (i.e. with no pleural effusion or other local advancement, no supraclavicular lymph node involvement and good performance status), but treated without resection.
  • The most common site of metastases in the entire series was brain, followed by liver, lymph nodes, bone, lung and skin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15200999.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Blanchard P, Plantade A, Pagès C, Afchain P, Louvet C, Tournigand C, de Gramont A: Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors. Gynecol Oncol; 2007 Jan;104(1):41-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors.
  • Isolated lymph node relapses (ILNR) are considered of relatively good prognosis with intensive therapy.
  • After initial optimal treatment, median progression-free survival (PFS) was 26 months.
  • Sites of relapse were retroperitoneum (n=15), left supraclavicular (n=7), mediastinum (n=4), iliac (n=4) and inguinal (n=3).
  • Treatment modalities were surgery in eight patients (30%), chemotherapy in 15 (55%) and radiotherapy in 5 patients (18%), alone or in combination.
  • Median OS from initial diagnosis was 68 months.
  • Time to relapse may not have its usual prognostic value.
  • Immediate or delayed therapy should be discussed in case of asymptomatic ILNR.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952391.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, Grigsby PW: Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol; 2010 Apr 20;28(12):2108-13
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.
  • PURPOSE A previous retrospective study demonstrated that positron emission tomography with [(18)F]fluorodeoxyglucose (FDG-PET) was more sensitive than computed tomography for lymph node staging in patients with cervical cancer; the findings on FDG-PET were strongly associated with progression-free survival.
  • Therefore, a prospective cohort study was initiated to evaluate FDG-PET lymph node staging in a larger patient population.
  • All 560 patients with cervical cancer underwent pretreatment FDG-PET lymph node staging.
  • Treatment included surgery alone, surgery and postoperative radiation therapy, and definitive radiation or combination radiation and chemotherapy.
  • Results Overall, 47% of patients had lymph node involvement by FDG-PET at diagnosis.
  • The frequency of lymph node metastasis increased with clinical stage and was similar to that in historical surgical series.
  • Within a stage, patients with PET-positive lymph nodes had significantly worse disease-specific survival than those with PET-negative lymph nodes (P < .001).
  • Disease-specific survival was stratified into distinct groups based on the most distant level of PET-detected nodal disease (none, pelvic, para-aortic, or supraclavicular; P < .001).
  • The hazard ratios for disease recurrence increased incrementally based on the most distant level of nodal disease: pelvic 2.40 (95% CI, 1.63 to 3.52), para-aortic 5.88 (95% CI, 3.80 to 9.09), and supraclavicular 30.27 (95% CI 16.56 to 55.34).
  • [MeSH-major] Fluorodeoxyglucose F18. Lymph Nodes / radionuclide imaging. Neoplasm Staging / methods. Positron-Emission Tomography. Radiopharmaceuticals. Uterine Cervical Neoplasms / radionuclide imaging
  • [MeSH-minor] Chemotherapy, Adjuvant. Chi-Square Distribution. Female. Gynecologic Surgical Procedures. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Predictive Value of Tests. Proportional Hazards Models. Prospective Studies. Radiotherapy, Adjuvant. Recurrence. Registries. Risk Assessment. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20308664.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


9. Shibata K, Kametani T, Takase M, Chatani K, Masuda S: [A case of adenocarcinoma of unknown primary site successfully treated with gemcitabine monotherapy]. Gan To Kagaku Ryoho; 2006 Oct;33(10):1489-92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 68-year-old female diagnosed with adenocarcinoma of unknown primary site (ACUP) by biopsy of supraclavicular lymph node was admitted to our department because of progressive dyspnea with cough.
  • The diagnosis of multiple lung metastases and malignant pleural effusion was made.
  • After 10 cycles, the chemotherapy was terminated.
  • The re-treatment with gemcitabine was started, and a good response was obtained again.
  • Gemcitabine monotherapy can be one of the treatment options for ACUP.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / analogs & derivatives. Lung Neoplasms / secondary. Neoplasms, Unknown Primary / drug therapy
  • [MeSH-minor] Aged. Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Pancreatic Neoplasms / diagnosis. Pleural Effusion, Malignant / drug therapy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033244.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / DU-PAN-2 antigen, human; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


10. Yung RC: Tissue diagnosis of suspected lung cancer: selecting between bronchoscopy, transthoracic needle aspiration, and resectional biopsy. Respir Care Clin N Am; 2003 Mar;9(1):51-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue diagnosis of suspected lung cancer: selecting between bronchoscopy, transthoracic needle aspiration, and resectional biopsy.
  • In pursuing a tissue diagnosis of a suspected lung cancer, there is a range of procedures to choose from.
  • The principal goals are ideally to diagnose and pathologically stage the patient's lung cancer at the same time, preferably by using the safest, least invasive, and least costly tests.
  • If there is clinical or radiographic evidence of extrapulmonary spread of disease, including supraclavicular N3 nodal involvement or a malignant pleural effusion, then radiology-guided or open biopsy will confirm tumor cell type and stage the patient as unresectable.
  • Bronchoscopy with direct examination of the visible airways is most often the preferred invasive diagnostic procedure.
  • Although the procedure should be geared toward sampling the highest staged lesion to provide an accurate tissue staging at the time of diagnosis, additional procedures can be performed in sequence to sample different nodal stations, is well as the primary lung mass.
  • The incidental finding of an unexpected central airways lesions or a synchronous second endobronchial lung primary will also affect plans for treatment.
  • Autofluorescence bronchoscopy can improve the sensitivity for detecting early intraepithelial neoplasia.
  • For visible endobronchial lesions, given the similar yield of EBBX and EBNA, EBNA may provide an immediate diagnosis, thus obviating additional, possibly morbid, procedures such as BB or EBBX.
  • Under all circumstances, immediate cytology feedback with ROSE will confirm the adequacy of the retrieved specimen for a definitive tissue diagnosis, thus avoiding the need for extra biopsies, or worse yet, the need for a second invasive procedure because of insufficient diagnostic material.
  • The diagnostic sensitivity of TTNA is high, especially for the larger peripheral-based lung lesion, and TTNA is a relatively rapid procedure.
  • Furthermore, TTNA usually does not provide information about nodal staging, unless the TTNA is initially directed toward central lymph nodes.
  • TTNA may then provide the tissue diagnosis to permit initiation of cytotoxic chemotherapy and radiotherapy.
  • TTNA may also be helpful in cases where the likelihood of cancer is only intermediate, such that a specific benign diagnosis or an adequate sample without cancer will greatly reduce the likelihood ratio of missing a cancer, and justify to the patient and physician an approach of careful observation.
  • Definitive curative surgery remains the goal for patients with lung cancer, with accurate pathological staging performed intraoperatively.
  • Therefore, for patients with sufficient cardiopulmonary reserve who can be clinically staged as IA or IB, either by good quality CT with contrast or increasingly with 18-FDG PET, the initial tissue diagnosis may be at the time of surgery, when a frozen section preceding a complete lobectomy with lymph node sampling will combine diagnosis and therapy.
  • [MeSH-major] Biopsy, Needle / methods. Bronchoscopy / methods. Cytodiagnosis. Lung Neoplasms / diagnosis. Mediastinal Neoplasms / diagnosis. Thoracic Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820712.001).
  • [ISSN] 1078-5337
  • [Journal-full-title] Respiratory care clinics of North America
  • [ISO-abbreviation] Respir Care Clin N Am
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA58184
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 159
  •  go-up   go-down


11. Ueda T, Emoto M, Fukuoka M, Miyahara D, Horiuchi S, Tsujioka H, Kawarabayashi T: Primary leiomyosarcoma of the fallopian tube. Int J Clin Oncol; 2010 Apr;15(2):206-9
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary sarcoma of the fallopian tube is a very rare neoplasm.
  • The preoperative diagnosis was a left adnexal malignant tumor based on pelvic examination, abdominal computed tomography, and magnetic resonance imaging.
  • She was treated with total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic lymph node dissection, partial omentectomy, and low anterior resection for rectal invasion.
  • The patient subsequently received adjuvant chemotherapy with pirarubicin and ifosfamide.
  • Thirty months after the first therapy, a computed tomography scan revealed metastasis of the liver, lung, and supraclavicular lymph node.
  • The patient died of the disease 39 months after the initial treatment.
  • [MeSH-major] Fallopian Tube Neoplasms / diagnosis. Leiomyosarcoma / diagnosis
  • [MeSH-minor] Aged. Biopsy. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Hysterectomy. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Magnetic Resonance Imaging. Omentum / surgery. Ovariectomy. Rectum / pathology. Rectum / surgery. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1996 Apr;61(1):27-30 [8626112.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):460-9 [12798712.001]
  • [Cites] J Obstet Gynaecol Br Commonw. 1973 Aug;80(8):759-60 [4725957.001]
  • [Cites] Acta Obstet Gynecol Scand. 1992 Apr;71(3):224-5 [1317647.001]
  • [Cites] Cancer. 1983 Aug 15;52(4):626-32 [6344983.001]
  • [Cites] Br J Radiol. 2008 Jan;81(961):73-81 [17681989.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):329-34 [18534250.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):363-6 [16439005.001]
  • [Cites] Eur J Gynaecol Oncol. 2005;26(3):333-5 [15991540.001]
  • [Cites] Gynecol Oncol. 1993 Dec;51(3):404-7 [8112653.001]
  • [Cites] Am J Obstet Gynecol. 1958 Jan;75(1):180-2 [13487699.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1498-506 [15042685.001]
  • [Cites] Zentralbl Gynakol. 1997;119(5):237-40 [9281259.001]
  • (PMID = 20191300.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Seishima M, Shimizu H, Oyama Z: Skin metastasis of breast cancer clinically undistinguished from amyopathic dermatomyositis. Eur J Dermatol; 2001 Mar-Apr;11(2):131-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Supraclavicular lymph node metastasis was found at the beginning of May, 1998.
  • A diagnosis of amyopathic dermatomyositis associated with breast cancer was made.
  • Treatment with radiation and chemotherapy reduced lymph node swelling, but complete remission was not obtained.
  • A diagnosis of skin metastasis of breast cancer was made.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / pathology. Dermatomyositis / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Back. Diagnosis, Differential. Fatal Outcome. Female. Humans. Lymphatic Metastasis. Neoplasm Recurrence, Local


13. Lee S, Park SY, Hong EK, Ro JY: Lymphoepithelioma-like carcinoma of the ovary: a case report and review of the literature. Arch Pathol Lab Med; 2007 Nov;131(11):1715-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 51-year-old woman presenting with low abdominal pain was found to have a right ovarian mass and enlarged pelvic, left para-aortic, and left supraclavicular lymph nodes.
  • Based on a clinical diagnosis of right ovarian carcinoma with lymph node metastases, she received 9 cycles of chemotherapy, resulting in a reduction of her ovarian tumor, disappearance of the enlarged pelvic and para-aortic lymph nodes, and normalization of serum CA 125 level.
  • However, there was no viable tumor in either supraclavicular or para-aortic lymph nodes.
  • [MeSH-major] Carcinoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. CA-125 Antigen / blood. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979492.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-125 Antigen
  • [Number-of-references] 16
  •  go-up   go-down


14. Grigsby PW, Siegel BA, Dehdashti F, Mutch DG: Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys; 2003 Mar 15;55(4):907-13
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the effect of irradiation and chemotherapy for carcinoma of the uterine cervix on posttreatment tumor uptake of the glucose analog (18)F-fluorodeoxyglucose (FDG) imaged by positron emission tomography (PET) and to assess the utility of FDG-PET for surveillance monitoring.
  • MATERIALS AND METHODS: This was a retrospective review of 76 patients with a new diagnosis of carcinoma of the uterine cervix who underwent pre- and posttreatment whole-body FDG-PET.
  • RESULTS: After treatment, persistent abnormal FDG uptake in the cervix was found in 18% (14 of 76), in the pelvic lymph nodes in 16% (9 of 55), in the paraaortic lymph nodes in 45% (5 of 11), and in the supraclavicular lymph nodes in 75% (3 of 4).
  • Eleven patients developed new sites of increased FDG uptake.
  • In relation to the findings on posttreatment PET, the 2-year progression-free survival rate was 86% for patients with no abnormal FDG uptake at any site and 40% for those with persistent abnormal uptake; there were no survivors at 2 years among patients who developed new sites of abnormal FDG uptake (p <0.0001).
  • CONCLUSIONS: FDG-PET is a valuable tool to evaluate the response of primary cervical carcinoma and lymph node metastasis to treatment and for the surveillance of patients after initial therapy.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radionuclide imaging. Adenocarcinoma / radiotherapy. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / radionuclide imaging. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / radiotherapy. Disease Progression. Disease-Free Survival. Female. Humans. Lymphatic Metastasis / radionuclide imaging. Multivariate Analysis. Neoplasm Recurrence, Local. Retrospective Studies. Tomography, Emission-Computed


15. Batori M, Ruggieri M, Chatelou E, Straniero A, Mariotta G, Palombi L, Casella G, Basile M, Casella MC: Breast cancer in young women: case report and a review. Eur Rev Med Pharmacol Sci; 2006 Mar-Apr;10(2):51-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast-conserving surgery with subsequent chemo-radiotherapy has become the treatment of choice in women with breast neoplasm.
  • One patient with an atypical medullary breast carcinoma diagnosis, pT2 pN1 bipMx, Grade 3 Stage IIB, negative for receptors, Ki 67: 47%, cERB-2 negative; the other with an intraductal breast carcinoma, pT1c pN0 pMx, Grade 2 Stage I, negative for receptors, Ki 67: 85%, cERB-2 negative, p53 negative, Bcl-2 negative.
  • Madden and axillary lymphoadenectomy in October 2001, started six cycles of adjuvant chemotherapy and radiotherapy on the right side of the chest and on axillary and supraclavicular lymph nodes area.
  • After the surgical therapy, she follows another adjuvant chemotherapy.
  • Like the first-will follow several cycles of adjuvant chemotherapy and radiotherapy.
  • Breast conservative surgery with chemio-radiotherapy is the most commonly used treatment breast cancer, expecially in consideration of the aggressiveness of the lesions.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Medullary / surgery. Lymph Node Excision. Mastectomy, Radical
  • [MeSH-minor] Adult. Age Factors. Axilla / surgery. Combined Modality Therapy. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging. Pedigree

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16705948.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 6
  •  go-up   go-down


16. Galmarini CM, Garbovesky C, Galmarini D, Galmarini FC: Clinical outcome and prognosis of patients with inflammatory breast cancer. Am J Clin Oncol; 2002 Apr;25(2):172-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peau d'orange was the most common clinical finding at diagnosis (65%).
  • A palpable breast mass (PBM) was noted in 65% with axillary lymph node involvement in 81% of patients.
  • Initial metastases included supraclavicular nodes (five of eight), bones (one of eight), skin (one of eight), and liver (one of eight).
  • All patients were treated with neoadjuvant chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil, 18 patients; other, 8 patients).
  • Only one patient was treated with total mastectomy after neoadjuvant chemotherapy, and 19 patients received radiotherapy followed (2 patients) or not (17 patients) by mastectomy.
  • Mean time-to-progression was 13 months (Kaplan-Meier estimates of 45% and 11% at 24 and 48 months, respectively).
  • By Kaplan-Meier method and log-rank test, a better OS was correlated with stage IIIB (p = 0.002), a PBM at diagnosis (p = 0.01), and a favorable response to initial chemotherapy (p = 0.03).
  • Our results confirm the better clinical outcome of patients with stage IIIB and PBM at diagnosis.
  • They also support the role for combined treatment as the best modality approach for this disease.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Mastectomy. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11943897.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Skugor ND, Perić Z, Vrhovac R, Radić-Kristo D, Kardum-Skelin I, Jaksić B: Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma. Coll Antropol; 2010 Mar;34(1):241-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
  • We report a case of AITL in which diffuse large B-cell lymphoma arose 13 months after the initial diagnosis of AITL.
  • In a 36-year-old female patient, evaluated for moderate leukocytosis, peripheral and abdominal lymphadenopathy AITL was diagnosed in March 2008, based on results of fine-needle aspiration cytology (FNAC) of the enlarged cervical and supraclavicular lymph nodes.
  • The diagnosis was also confirmed by immunophenotyping and histopathology of the cervical lymph nodes.
  • The patient initially recieved FED chemotherapy (fludarabine, cyclophosphamide, dexamethasone) followed by elective autologous hematopoietic stem cell transplantation.
  • The FNAC of the enlarged cervical lymph nodes was performed again, but this time the smears were composed of polymorphous population of lymphocytes with the predomination of large cells, CD20+ on immunocytochemical stains.
  • CHOP-R chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) was then administered, resulting in good partial response of the disease.
  • AITL is a rare lymphoproliferative disorder in which the neoplastic T-cells represent the minority of the lymph node cell population and almost all cases harbor EBV-infected B-cells.
  • Various authors postulated that immunodeficiency in AITL patients together with immunosuppressive effects of cytotoxic drugs, may be responsible for EBV-induced proliferation of latently or newly EBV-infected B-cells with eventual clonal selection and progression to aggressive B-cell lymphoma.
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Fine-Needle. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Epstein-Barr Virus Infections / pathology. Female. Humans. Immunophenotyping. Neoplasm Recurrence, Local / pathology. Prednisone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432757.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


18. Piperkova E, Raphael B, Altinyay M, Castellon I, Libes R, Sandella N, Abdel-Dayem H: Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review. J BUON; 2006 Oct-Dec;11(4):523-7
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review.
  • Distant extrapelvic metastases appear in approximately in 10% of the patients with squamous cell anal cancer (SCAC) and survival depends on the treatment strategy.
  • Exact staging leads to optimal planning of multimodality therapy and the adequate evaluation of treatment response can improve the prognosis of the disease.
  • Diagnosis and staging of SCAC are commonly performed using contrast-enhanced computerized tomography(CT) and interpretation of the findings for tumor biological behavior.
  • F18-fluoro-2 deoxy-D glucose positron emission tomography((18)F-FDG PET) reveals aspects of tumor function and allows metabolic measurements.
  • Radiation therapy (RT) and chemotherapy achieved a good therapeutic response but early follow up revealed new paraaortic lymph node (LN) metastases, as well as an uncommon left supraclavicular LN metastasis from the same primary carcinoma.
  • The disease was restaged as stage IV (T2N2M1) and radiation therapy was substituted by chemotherapy.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed
  • [MeSH-minor] Combined Modality Therapy. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Patient Care Management. Prognosis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309188.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


19. Zang RY, Zhang ZY, Cai SM, Tang MQ, Chen J, Li ZT: Epithelial ovarian cancer presenting initially with extraabdominal or intrahepatic metastases: a preliminary report of 25 cases and literature review. Am J Clin Oncol; 2000 Aug;23(4):416-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-five patients with EOC, who were treated in the Cancer Hospital of Shanghai Medical University from January 1986 to December 1997, and manifesting as extraperitoneal or liver parenchyma metastases at the time of presentation without detectable ovarian tumors, were retrospectively studied.
  • When compared with 52 other women with stage IV EOC, 20 patients who initially sought treatment for extraabdominal metastases experienced a better prognosis, with an estimated median survival of 24 months versus 10 months (p = 0.0427).
  • The median survival was 30 months in patients with pleural effusion or supraclavicular lymph node metastases versus 19 months in those with spread to other sites (p = 0.0264).
  • The prognosis of such cases, mainly for those with supraclavicular lymphadenopathy or malignant pleural effusion, is better than that for other stage IV EOC patients, probably because most of the patients who initially had distant metastases were generally in condition that permitted aggressive surgery or multicycle chemotherapy.
  • [MeSH-major] Carcinoma / diagnosis. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Adult. Aged. CA-125 Antigen / analysis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Linear Models. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pleural Effusion, Malignant / diagnosis. Prognosis. Remission Induction. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10955875.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / CA-125 Antigen
  • [Number-of-references] 13
  •  go-up   go-down


20. Kushner BH, LaQuaglia MP, Kramer K, Cheung NK: Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk. J Pediatr Hematol Oncol; 2004 Jan;26(1):35-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk.
  • Neuroblastoma risk stratification is based on stage, age, and biology and prescribes surgery for low-risk disease, moderate-dose chemotherapy for intermediate-risk disease, and maximal therapy (including myeloablative treatment with stem cell transplantation) for high-risk disease.
  • The first recommendations were for maximal therapy, but second opinions were radically different (ie, surgery alone).
  • Ages at diagnosis were 15 to 25 months.
  • All four patients did well without cytotoxic therapy (follow-up: 2 years 10 months plus to 4 years 8 months plus).
  • Patient 1 had abdominal and upper thoracic/supraclavicular masses (stage 4); the former was resected and the latter spontaneously regressed.
  • Biopsies of the latter showed no neuroblastoma and the primary tumor (with regional lymph nodes) was resected, changing stage from 4 to 2B.
  • Patient 4 had a pelvic mass, with unfavorable histopathology, and bilateral inguinal lymph node involvement (stage 3); all soft tissue disease was resected.
  • Some patients classified as having high-risk neuroblastoma might actually do well with no cytotoxic therapy.
  • [MeSH-major] Health Planning Guidelines. Neuroblastoma / diagnosis. Neuroblastoma / surgery
  • [MeSH-minor] Biomarkers / analysis. Child, Preschool. Diagnostic Imaging. Female. Humans. Infant. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14707711.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


21. Kanamori M, Ohmori K, Nogami S, Maeda Y: Undifferentiated leiomyosarcoma showing various sarcomatous components with incidental B-cell lymphoma after tumor recurrence. J Orthop Sci; 2002;7(6):698-702
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathological diagnosis of repeated surgery was undifferentiated LMS that included various sarcomatous components, such as fibrosarcomatous, rhabdomyosarcomatous, and malignant fibrous histiocytoma-like elements.
  • A specimen from a supraclavicular lymph node showed the characteristics of malignant B-cell lymphoma (follicle type).
  • Adjuvant chemotherapy or radiation therapy was not performed because of the patient's advanced age.
  • The patient died from liver metastasis and dysfunction 5 years 8 months after the initial therapy.
  • Considerable debate remains whether the B-cell lymphoma developed incidentally.
  • [MeSH-major] Leiomyosarcoma / pathology. Lymphoma, B-Cell / pathology. Muscle Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12486476.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Scheinpflug K, Schmitt J, Jentsch-Ullrich K, Roessner A, Franke A: Thymic hyperplasia following successful treatment for nodular-sclerosing Hodgkin's disease. Leuk Lymphoma; 2003 Sep;44(9):1615-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic hyperplasia following successful treatment for nodular-sclerosing Hodgkin's disease.
  • A young female patient showed up with mediastinal bulky disease and lymph node swelling in her left supraclavicular region.
  • The patient received combined modality treatment according to the protocols of the German Hodgkin's Disease Study Group and achieved complete remission.
  • Thymic hyperplasia is well known as a potential differential diagnosis of mediastinal space-occupying lesions and also as a long-term complication in patients cured of Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / drug therapy. Thymus Gland / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Hyperplasia. Mediastinal Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Remission Induction. Thymectomy

  • Genetic Alliance. consumer health - Thymic hyperplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14565667.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 14
  •  go-up   go-down


23. Stoelben E, Ludwig C: Chest wall resection for lung cancer: indications and techniques. Eur J Cardiothorac Surg; 2009 Mar;35(3):450-6
Genetic Alliance. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is a problem concerning correct diagnosis: many tumours reach the chest wall.
  • We do not want to perform over-treatment since lung resection en bloc with the chest wall has a higher morbidity and mortality than lobectomy.
  • The prognosis of patients with tumours invading the chest wall and mediastinal lymph node metastasis is worse.
  • But patients with ipsilateral supraclavicular lymph node metastasis are not excluded.
  • The use of modern pain treatment is very important.
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis / pathology. Male. Neoplasm Invasiveness. Neoplasm Staging. Pain, Postoperative / drug therapy. Pleura / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188079.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 38
  •  go-up   go-down






Advertisement